Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Iron Deficiency Injectable Market Value Expansion And Long-Term Growth Outlook
The market for injectable iron deficiency treatments has experienced robust expansion recently. Projections indicate a notable increase, with the market value set to climb from $15.22 billion in 2025 to $16.74 billion in 2026, reflecting a compound annual growth rate of 10.0%. Factors driving this historical growth trajectory include the widespread occurrence of iron deficiency anemia, the relative limitations of oral iron treatments, a rising incidence of chronic kidney disease, the proliferation of intravenous infusion therapies in healthcare settings, and a growing acceptance of iron injections within clinical practice.
The market for injectable iron deficiency treatments is poised for substantial expansion in the coming years, projecting a market value of $25.69 billion by 2030 with an anticipated compound annual growth rate of 11.3%. This anticipated surge is underpinned by several key factors, including an increasing elderly demographic, a higher incidence of cancer and inflammatory bowel disease, the broadening availability of home infusion services, enhanced safety characteristics of recently developed formulations, and improved healthcare accessibility in developing economies. Key market developments expected during this forecast period encompass a growing inclination towards injectable iron therapies over oral alternatives, their increased utilization in managing chronic kidney disease, the rise of outpatient and brief infusion procedures, the proliferation of generic injectable iron options, and a greater uptake in the treatment of oncological and chronic conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp
Iron Deficiency Injectable Market Growth Momentum: Which Factors Are Influencing Demand?
The escalating incidence of polycystic ovary syndrome (PCOS) is anticipated to be a significant catalyst for the expansion of the iron deficiency injectables market in the coming period. This prevalent hormonal condition, polycystic ovary syndrome (PCOS), impacts individuals with ovaries, predominantly women during their childbearing years, leading to iron accumulation. This condition consequently results in substantial blood loss during menstrual cycles, causing anemia in patients, which can be effectively treated with injectable iron deficiency therapies. As an illustration, data from June 2023, provided by the World Health Organization, a specialized health entity based in the United States, indicates that polycystic ovary syndrome (PCOS) affects approximately 8% to 13% of women of reproductive age worldwide, with a striking 70% of these individuals remaining undiagnosed. Consequently, the widespread occurrence of polycystic ovary syndrome (PCOS) is directly fueling the advancement of the iron deficiency injectables market.
Iron Deficiency Injectable Market Segment Landscape And Growth Potential
The iron deficiency injectable market covered in this report is segmented –
1) By Type: Iron Dextran, Ferric Carboxymaltose
2) By Branded or Generics: Branded, Generics
3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Ferric Carboxymaltose: Injectafer, Ferinject
Iron Deficiency Injectable Market Trends Reshaping Industry Growth
The iron deficiency injectables market is being shaped by leading pharmaceutical entities introducing novel treatments like INJECTAFER to solidify their market standing. As an illustration, Daiichi Sankyo Company, a US healthcare firm, and American Regent Inc., a U.S. manufacturer of injectable drugs, introduced INJECTAFER (ferric carboxymaltose injection) in June 2023 for treating iron deficiency, following its authorization by the U.S. Food and Drug Administration (FDA). Notably, this marks the inaugural and sole FDA-approved intravenous iron replacement therapy specifically for adult individuals experiencing chronic and progressive heart failure. The efficacy of INJECTAFER has been substantiated through an extensive analysis of over 40 clinical trials, encompassing more than 8,800 participants globally. This recent endorsement further reinforces the established and proven utility of INJECTAFER in managing iron-deficient anemia and heart failure among both adult and pediatric populations.
Iron Deficiency Injectable Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.
Access The Complete Iron Deficiency Injectable Market Report:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Iron Deficiency Injectable Market Regional Analysis And Leading Geography
North Americawas the largest region in the iron deficiency injectable market in 2025. The regions covered in the iron deficiency injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
